MiNK Therapeutics (INKT)
NASDAQ:INKT
Want to see INKT full AI Analyst Report?
INKT Stock Chart & Stats
$14.13
-$0.11(-11.96%)
At close: 4:00 PM EST
$14.13
-$0.11(-11.96%)
Day’s Range― - ―
52-Week Range$6.34 - $76.00
Previous CloseN/A
Volume98.55K
Average Volume (3M)39.56K
Market Cap
$64.26M
Enterprise Value-$13.28B
Total Cash (Recent Filing)$13.36B
Total Debt (Recent Filing)$5.18M
Price to Earnings (P/E)―
Beta0.04
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding4,965,858
10 Day Avg. Volume31,712
30 Day Avg. Volume39,559
Financial Highlights & Ratios
PEG Ratio-3.68
Price to Book (P/B)-3.35
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-206.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit73.09K
Enterprise Value/Ebitda1.08K
Forecast
1Y Price Target
$35.00Price Target Upside147.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAnalyst highlights a company-sponsored Phase 2 trial in severe pulmonary disease with a primary mortality endpoint that aligns with FDA approval expectations, supporting a clear regulatory pathway.
Manufacturing And Treatment AccessAnalyst emphasizes the allogeneic off-the-shelf iNKT platform that removes the need for patient-specific manufacturing and toxic lymphodepleting chemotherapy, enabling faster treatment for fragile patients.
Target Validation And CollaborationAnalyst notes a strategic collaboration to develop a PRAME-targeted TCR-engineered iNKT cell therapy, expanding the company's program into pediatric and adult cancers against a highly selective antigen.
Bears Say
Financing RiskAnalyst expects the Phase 2 trial to rely largely on external capital, increasing dependence on outside financing and the risk of shareholder dilution.
Related-party Debt ExposureAnalyst points out debt tied to a related-party note from a partner, representing a potential financial obligation that could limit financial flexibility.
MiNK Therapeutics News
INKT FAQ
What was MiNK Therapeutics’s price range in the past 12 months?
MiNK Therapeutics lowest stock price was $6.34 and its highest was $76.00 in the past 12 months.
What is MiNK Therapeutics’s market cap?
MiNK Therapeutics’s market cap is $64.26M.
When is MiNK Therapeutics’s upcoming earnings report date?
MiNK Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 25 days.
How were MiNK Therapeutics’s earnings last quarter?
MiNK Therapeutics released its earnings results on Mar 31, 2026. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.77 by $0.25.
Is MiNK Therapeutics overvalued?
According to Wall Street analysts MiNK Therapeutics’s price is currently Undervalued.
Does MiNK Therapeutics pay dividends?
MiNK Therapeutics does not currently pay dividends.
What is MiNK Therapeutics’s EPS estimate?
MiNK Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MiNK Therapeutics have?
MiNK Therapeutics has 4,965,858 shares outstanding.
What happened to MiNK Therapeutics’s price movement after its last earnings report?
MiNK Therapeutics reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.77. Following the earnings report the stock price went up 0.095%.
Which hedge fund is a major shareholder of MiNK Therapeutics?
Currently, no hedge funds are holding shares in INKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MiNK Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (147.70% Upside)
$35.00 (147.70% Upside)
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $27.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-75.93%
Trailing 12-Months
Company Description
MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
INKT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple substantive clinical and translational wins (durable oncology responses, strong ARDS signals, initiation of randomized pulmonary and GvHD programs), meaningful nondilutive funding and improved capital efficiency (cash up ~191%, operating costs down ~40%). However, the company remains early‑stage with ongoing net losses (FY loss up ~16%), a limited runway extended only through 2026, and some program timing and partnership uncertainties. On balance the strength of the clinical data, funding traction and disciplined cost reduction outweigh near‑term financial and operational risks.View all INKT earnings summariesINKT Stock 12 Month Forecast
Average Price Target
$35.00
▲(147.70% Upside)
Technical Analysis
Ownership Overview
4.83% Insiders
1.49% Mutual Funds
0.90% Other Institutional Investors
91.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---